Triplet vs. doublet chemotherapy plus bevacizumab boosts PFS for colorectal cancer subset
Click Here to Manage Email Alerts
For patients with unresectable colorectal cancer liver metastases and right-sided RAS or BRAF mutations, FOLFOXIRI plus bevacizumab vs. FOLFOX/FOLFIRI plus bevacizumab significantly increased PFS, according toASCO Annual Meeting results.
"Triplet vs. doublet chemotherapy plus bevacizumab significantly increases progression-free survival, response rate and successful local treatments as defined by R0/R1 resection plus or minus ablation rates," Cornelis J.A. Punt, MD, PhD, professor in the medical oncology department at Academic Medical Centre, Amsterdam, The Netherlands, said during an oral abstract session on the CAIRO5 study.
He said that these results come at the cost of "increased but manageable toxicity."
"CAIRO5 is the first randomized study that prospectively evaluates systemic induction regiments in patients with initially unresectable [colorectal cancer liver metastasis] according to predefined criteria by a central liver expert panel," Punt said.
In addition, Punt commented on the feasibility of the expert liver panel, saying it allows for more eligible patients to be selected for treatment.
Between December 2014 and March 2021, the Dutch multicenter, randomized, phase 3 clinical study evaluated a total of 291 patients who were randomized into two arms. Arm A (n= 147) received FOLFOX or FOLFIRI plus bevacizumab and arm B (n = 144) received FOLFOXIRI plus bevacizumab. Both arms received 12 cycles of treatment followed by 5-fluorouracil, leucovorin and bevacizumab maintenance.
Collapse
Click Here to Manage Email Alerts